China Meheco Group (SHA:600056), through subsidiary Tianfang Pharmaceutical, received two drug supplementary approvals for clindamycin phosphate injection after passing the Chinese drug regulator's consistency evaluation for quality and efficacy, according to a Shanghai bourse filing on Tuesday.
The approvals are for the drug's two specifications 4 milliliters and 2 milliliters.
The drug is used to treat serious infections caused by susceptible anaerobic bacteria, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。